SCHEMBL95649

SCHEMBL95649

[CH2]c1ccc(NS(=O)(=O)c2ccccc2OC)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 1/20 0.55
PTPN2 P17706 3/20 0.55
PTPN1 P18031 3/20 0.55
PTPN5 P54829 3/20 0.55
PKM P14618 3/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
LMNA P02545 2/20 0.53
ALOX12 P18054 1/20 0.53
BRD4 O60885 6/20 0.53
HSPD1 P10809 1/20 0.53
HSPE1 P61604 1/20 0.53
HTT P42858 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NAMPT P43490 1/20 0.52
BRD1 O95696 1/20 0.51
BRPF1 P55201 1/20 0.51
ALDH1A1 P00352 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP19A1 P11511 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7364604 0.87 CA12 (0.59) SLC22A12PTPN2PTPN1PTPN5PKM
SCHEMBL5305683 0.86 LMNA (0.66) SLC22A12PTPN2PTPN1PTPN5PKM
SCHEMBL95050 0.81 ALPL (0.61) PKMMEN1KMT2ALMNAHTT
SCHEMBL95715 0.81 SMN1; SMN2 (0.71) MEN1KMT2ALMNAALOX12SMN1; SMN2
SCHEMBL95622 0.81 ALPL (0.58) SLC22A12BRD4CYP2C9
SCHEMBL95201 0.80 NPSR1 (0.69) PTPN2PTPN1PTPN5LMNAHTT
SCHEMBL95378 0.79 ALDH1A1 (0.56) SLC22A12PTPN2PTPN1PTPN5PKM
SCHEMBL7569855 0.78 SLC22A12 (0.58) SLC22A12PTPN2PTPN1PTPN5PKM
SCHEMBL96178 0.78 KMT2A (0.63) PTPN2PTPN1PTPN5MEN1KMT2A
SCHEMBL2371547 0.76 HTR6 (0.55) SLC22A12PKMBRD4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB SLC22A12 3575/4885PTPN2 1202/4885PTPN1 1236/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 SLC22A12 2298/4885PTPN2 2099/4885PTPN1 1691/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 SLC22A12 2298/4885PTPN2 2099/4885PTPN1 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.